Quantinno Capital Management LP Acquires 7,270 Shares of Insulet Co. (NASDAQ:PODD)

Quantinno Capital Management LP raised its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 118.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,416 shares of the medical instruments supplier's stock after acquiring an additional 7,270 shares during the period. Quantinno Capital Management LP's holdings in Insulet were worth $3,123,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of PODD. Blue Trust Inc. raised its position in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after buying an additional 58 shares in the last quarter. International Assets Investment Management LLC acquired a new position in Insulet during the 2nd quarter worth approximately $32,000. Venturi Wealth Management LLC lifted its stake in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 133 shares during the last quarter. UMB Bank n.a. boosted its position in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock valued at $37,000 after buying an additional 81 shares in the last quarter. Finally, 1620 Investment Advisors Inc. bought a new stake in shares of Insulet during the second quarter worth $52,000.

Insulet Stock Up 4.4 %

Shares of PODD stock traded up $11.75 on Tuesday, reaching $276.87. 420,867 shares of the company were exchanged, compared to its average volume of 762,267. Insulet Co. has a one year low of $160.19 and a one year high of $279.40. The company has a market cap of $19.42 billion, a price-to-earnings ratio of 45.40, a PEG ratio of 4.06 and a beta of 1.21. The company has a 50-day moving average of $248.13 and a 200-day moving average of $217.98. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Analyst Upgrades and Downgrades

PODD has been the topic of several recent research reports. Morgan Stanley raised their price objective on Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a report on Monday, November 11th. Barclays boosted their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an "equal weight" rating in a report on Monday, November 11th. Canaccord Genuity Group raised their price target on shares of Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a research note on Monday. BTIG Research upped their price target on Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Finally, Piper Sandler raised their price objective on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $255.60.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.